Ferroptosis-centered Drug Response Information
General Information of the Drug (ID: ferrodrug0303)
| Name |
Go-6976
|
||||
|---|---|---|---|---|---|
| Synonyms |
136194-77-9; Go 6976; GO6976; Go-6976; Goe 6976; 3-(13-Methyl-5-oxo-6,7-dihydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazol-12(13H)-yl)propanenitrile; 5,6,7,13-Tetrahydro-13-Methyl-5-oxo-12H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-12-propanenitrile; B9IQO7JZ16; 12-(2-Cyanoethyl)-6,7,12,13-tetrahydro-13-methyl-5-oxo-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole; CHEMBL302449; CHEBI:51913; 12H-Indolo(2,3-a)pyrrolo(3,4-c)carbazole-12-propanenitrile, 5,6,7,13-tetrahydro-13-methyl-5-oxo-; 12H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-12-propanenitrile, 5,6,7,13-tetrahydro-13-methyl-5-oxo-; 12-(2-cyanoethyl)-6,7,12,13-tetrahydro-13-methyl-5-oxo-5H-indolo[2,3-a]pyrolo[3,4-c]carbazole; 3-(13-methyl-5-oxo-5,6,7,13-tetrahydro-12H-indolo[2,3-a]pyrrolo[3,4-c]carbazol-12-yl)propanenitrile; UNII-B9IQO7JZ16; Goe-6976; Kinome_3630; Gouml 6976; G ouml 6976; CBiol_001871; G? 6976; BSPBio_001101; KBioGR_000441; KBioSS_000441; 13-Methyl-5-oxo-5,6,7,13-tetrahydro-12H-indolo(2,3-a)pyrrolo(3,4-c)carbazole-12-propanenitrile; BDBM3033; GTPL5973; SCHEMBL2175239; BCBcMAP01_000156; KBio2_000441; KBio2_003009; KBio2_005577; KBio3_000821; KBio3_000822; DTXSID70159731; Bio1_000157; Bio1_000646; Bio1_001135; Bio2_000381; Bio2_000861; HMS1362G03; HMS1792G03; HMS1990G03; HMS3229E13; HMS3403G03; BCP06797; 3-[methyl(oxo)[?]yl]propanenitrile; EI-269; HB0302; s7119; AKOS024457007; AT23580; CCG-206755; IDI1_002136; NCGC00163451-01; NCGC00163451-02; NCGC00163451-03; NCGC00163451-04; AS-16804; BG168444; HY-10183; CS-0002498; FT-0697606; EC-000.2399; G?? 6976, >=98% (HPLC), powder; A924795; Go 6976 - CAS 136194-77-9; J-006821; BRD-K59304176-001-02-5; BRD-K59304176-001-03-3; Q27077832; 3-(13-methyl-5-oxo-5,6,7,13-tetrahydro-12H-indolo[2,3-a]pyrrolo[3,4-c]carbazol-12-yl)propionitrile; 3-(23-methyl-14-oxo-3,13,23-triazahexacyclo[14.7.0.0^{2,10.0^{4,9.0^{11,15.0^{17,22]tricosa-1,4,6,8,10,15,17,19,21-nonaen-3-yl)propanenitrile; 3-(23-methyl-14-oxo-3,13,23-triazahexacyclo[14.7.0.02,10.04,9.011,15.017,22]tricosa-1,4,6,8,10,15,17,19,21-nonaen-3-yl)propanenitrile; 3-(9-methyl-1-oxo-2,3-dihydro-1H-indolo[2,3-a]pyrrolo[3,4-c]carbazol-8(9H)-yl)propanenitrile; 3-{23-methyl-14-oxo-3,13,23-triazahexacyclo[14.7.0.0^{2,10}.0^{4,9}.0^{11,15}.0^{17,22}]tricosa-1(16),2(10),4(9),5,7,11(15),17,19,21-nonaen-3-yl}propanenitrile; 3-{23-methyl-14-oxo-3,13,23-triazahexacyclo[14.7.0.0^{2,10}.0^{4,9}.0^{11,15}.0^{17,22}]tricosa-1(16),2(10),4,6,8,11(15),17,19,21-nonaen-3-yl}propanenitrile
Click to Show/Hide
|
||||
| Structure |
 |
||||
| Formula |
C24H18N4O
|
||||
| IUPAC Name |
3-(23-methyl-14-oxo-3,13,23-triazahexacyclo[14.7.0.02,10.04,9.011,15.017,22]tricosa-1,4,6,8,10,15,17,19,21-nonaen-3-yl)propanenitrile
|
||||
| Canonical SMILES |
CN1C2=CC=CC=C2C3=C4C(=C5C6=CC=CC=C6N(C5=C31)CCC#N)CNC4=O
|
||||
| InChI |
InChI=1S/C24H18N4O/c1-27-17-9-4-2-7-14(17)20-21-16(13-26-24(21)29)19-15-8-3-5-10-18(15)28(12-6-11-25)23(19)22(20)27/h2-5,7-10H,6,12-13H2,1H3,(H,26,29)
|
||||
| InChIKey |
VWVYILCFSYNJHF-UHFFFAOYSA-N
|
||||
| PubChem CID | |||||
Full List of Ferroptosis Target Related to This Drug
Unspecific Target
| In total 1 item(s) under this Target | ||||
| Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target | [1] | |||
| Responsed Disease | Rhabdomyosarcoma | ICD-11: 2B55 | ||
| Responsed Regulator | Protein kinase C alpha type (PRKCA) | Driver | ||
| Pathway Response | Fatty acid metabolism | hsa01212 | ||
| Ferroptosis | hsa04216 | |||
| Cell Process | Cell ferroptosis | |||
| In Vitro Model | RD cells | Rhabdomyosarcoma | Homo sapiens | CVCL_1649 |
| Rh18 cells | Alveolar rhabdomyosarcoma | Homo sapiens | CVCL_1659 | |
| Rh30 cells | Alveolar rhabdomyosarcoma | Homo sapiens | CVCL_0041 | |
| Rh36 cells | Embryonal rhabdomyosarcoma | Homo sapiens | CVCL_M599 | |
| Rh41 cells | Alveolar rhabdomyosarcoma | Homo sapiens | CVCL_2176 | |
| T 174 cells | Rhabdomyosarcoma | Homo sapiens | CVCL_U955 | |
| TE 381.T cells | Rhabdomyosarcoma | Homo sapiens | CVCL_1751 | |
| KYM-1 cells | Embryonal rhabdomyosarcoma | Homo sapiens | CVCL_3007 | |
| Response regulation | Rhabdomyosarcoma (RMS) cells might be vulnerable to oxidative stress-induced cell death. The broad-spectrum protein kinase C (PKC) inhibitor Bisindolylmaleimide I as well as the PKC-a (PRKCA) and b-selective inhibitor Go-6976 significantly reduced Erastin-induced cell death. Furthermore, the broad-spectrum nicotinamide adenine dinucleotide phosphate-oxidase (NOX) inhibitor Diphenyleneiodonium and the selective NOX1/4 isoform inhibitor GKT137831 significantly decreased Erastin-stimulated ROS, lipid ROS and cell death. | |||